Cipla’s third quarter profit may jump 27 percent year-on-year to Rs 360.6 crore, according to the average of estimates of analysts polled by CNBC-TV18.
Cipla ‘s third quarter profit may jump 27 percent year-on-year to Rs 360.6 crore, according to the average of estimates of analysts polled by CNBC-TV18.
Revenue is seen going up 14 percent to Rs 2,940.5 crore in December quarter from Rs 2,581 crore in same quarter last fiscal.
Operating profit may climb 21.3 percent year-on-year to Rs 566.9 crore and margin may expand 120 basis points to 19.3 percent in Q3FY15.
Analysts feel the domestic formulation business of the drug maker could disappoint during the quarter following slow growth reported by other pharma companies. For instance in Q3, Lupin’s India growth was 14 percent (against 18 percent in Q2), Dr Reddy’s Labs India growth was 11 percent and Alembic formulations business grew 11 percent.
Cipla may report a 10-11 percent growth in exports in Q3FY15.
Progress on inhaler business will be key factor to watch out for in Q3.